Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Microfluidics, 3D-BioPrinting & BioFabrication 2020

Microfluidics, 3D-BioPrinting & BioFabrication 2020 Agenda

Print Agenda

Tuesday, 13 October 2020


Shulamit LevenbergKeynote Presentation

Title to be Confirmed.
Shulamit Levenberg, Professor and Dean, Faculty of Biomedical Engineering, Technion Israel Institute of Technology, Israel


Title to be Confirmed.
Orit Shefi, Head of Neuroengineering Laboratory, Faculty of Engineering and Institute of Nanotechnologies and Advanced Materials, Bar-Ilan University Israel, Israel


Joshua EdelKeynote Presentation

Title to be Confirmed.
Joshua Edel, Professor, Imperial College London, United Kingdom


Tal DvirKeynote Presentation

Engineering Personalized Tissue Implants: From 3D Printing to Bionic Organs
Tal Dvir, Professor, Director, Laboratory for Tissue Engineering and Regenerating Medicine, Tel Aviv University, Israel

In this talk I will describe cutting-edge technologies for engineering functional tissues and organs, including the heart, brain, spinal cord and retina. I will focus on the design of new biomaterials, mimicking the natural microenvironment, or releasing biofactors to promote stem cell recruitment and tissue protection. In addition, I will discuss the development of patient-specific materials and 3D-printing of personalized vascularized tissues and organs. Finally, I will show a new direction in tissue engineering, where, micro and nanoelectronics are integrated within engineered tissues to form cyborg tissues.


Patient-Specific BBB-on-Chip Platform Enables Predictive Personalized Medicine Applications
Gad Vatine, Senior Lecturer, Ben-Gurion University of the Negev, Israel

The blood brain barrier (BBB) is a multicellular neurovascular unit (NVU) in which pericytes, astrocytes, and neurons directly interact with brain microvascular endothelial cells (BMECs). In turn, BMECs form a specialized transporter barrier created by tight junctions and polarized efflux pumps. This fine-tuned cellular architecture permits the blood-to-central nervous system (CNS) passage of crucial nutrients and metabolic molecules while prohibiting the entry of deleterious factors and most drugs. Several neurological disorders involve BBB dysfunction, creating the need to understand BBB physiology and transport mechanisms in both health and disease. Marked differences in BBB substrate specificity and transporter activity across species limit the relevance of animal models. Therefore, a human-specific BBB model is crucial to study human diseases and for the discovery of new CNS permeable drugs.

Combining iPSC and organ-on-chip technologies we developed a novel platform in which isogenic iPSC-derived iBMECs, astrocytes and neurons mimic human BBB functionality. iBMECs form a bioengineered vessel-like structure on the Organ-Chip and human astrocytes, pericytes and neurons form direct cell-to-cell interactions that mimic functionality at the level of an organ. The BBB-Chip exhibits physiologically relevant transendothelial electrical resistance and faithfully predicts BBB permeability of molecules. Whole human blood perfusion through the ‘blood vessel’ introduces another physiological interphase and demonstrates that iBMECs can protect spontaneously active neurons from cytotoxicity. Finally, genetic neurological disease modeling in the context of a functional organ reveals substrate transport variability across individual BBB, demonstrating the feasibility of this approach for predictive personalized medicine applications.


Andrew StecklKeynote Presentation

Biofluids and Microfluidics – Point-of-Use Devices for Sensing Human Stress Biomarkers
Andrew Steckl, Gieringer Professor, Ohio Eminent Scholar, University Distinguished Research Professor, University of Cincinnati, United States of America

Hormones produced by glands in the endocrine system and neurotransmitters produced by the nervous system control many bodily functions. The concentrations of these molecules in the body are an indication of its state, hence the use of the term biomarker. Excess concentrations of biomarkers, such as cortisol, serotonin, epinephrine, dopamine, are released by the body in response to a variety of conditions - emotional state (euphoria, stress), disease, etc. The development of simple, low-cost modalities for point-of-use (PoU) measurements of biomarkers levels in various bodily fluids (blood, urine, sweat, saliva) as opposed to conventional hospital or lab settings is receiving increasing attention. The presentation starts with a review of the basic properties of primary stress-related biomarkers: origin in the body (produced as hormones, neurotransmitters or both), chemical composition, molecular weight (small/medium size molecules and polymers, ranging from ~100Da to ~100kDa), hydro- or lipo-philic nature. Next, a review of the published literature is presented regarding the concentration of these biomarkers found in several bodily fluids that can serve as the medium for determination of the condition of the subject: blood, urine, saliva, sweat and interstitial tissue fluid. The concentration of various biomarkers in most fluids covers a range of 5-6 orders of magnitude, from 100s of ng/mL (~1µM) down to a few pg/mL (sub 1pM). Mechanisms and materials for point-of-use biomarker sensors are summarized and key properties are reviewed. Illustrative examples from the literature are discussed for several sensor device categories, including capillary flow devices and microfluidic devices. Selected methods for detecting these biomarkers are reviewed, including antibody- and aptamer-based assays, electrochemical and optical detection. Finally, the presentation outlines key challenges of the field and provides a look ahead to future prospects.


Title to be Confirmed.
William Whitford, Strategic Solutions Leader, GE Healthcare Life Sciences, United States of America

Agenda is not currently available
Add to Calendar ▼2020-10-13 00:00:002020-10-14 00:00:00Europe/LondonMicrofluidics, 3D-BioPrinting and BioFabrication 2020Microfluidics, 3D-BioPrinting and BioFabrication 2020 in Tel Aviv, IsraelTel Aviv,